NEW YORK--Goldman Sachs (NYSE:GS) is recognizing Click Therapeutics, Inc.'s ("Click") co-founder and CEO, David Benshoof Klein, as one of the 100 Most Intriguing Entrepreneurs of 2019 at its Builders + Innovators Summit in Santa Barbara, California.

Goldman Sachs selected Mr. Klein as one of 100 entrepreneurs from multiple industries to be honored at the three-day event. Mr. Klein is an investor and entrepreneur with over 18 years of life science industry experience, and has played key roles in founding, financing and operating numerous life science companies. In 2012, Mr. Klein co-founded Click Therapeutics, a leader in the development and commercialization of software as medical treatments, and conceived of the term Digital Therapeutics to reference this now burgeoning industry.

"In the past year, our diverse team of engineers, designers, data scientists, product managers, clinicians, scientists, privacy and regulatory experts have made rapid progress across a broad pipeline of novel digital therapeutics, helping to position the company as the clear market leader in software as first-line medical treatments,” said CEO David Benshoof Klein. "Patients and prescribers can have confidence in the work of our team as we put our software treatments through the same rigorous quality controls, clinical validation, and regulatory review as traditional medical devices and drugs. Further, our products leverage the latest in user experience design principles and data security methodology to put the needs of the patient at the center. We are excited to bring these novel, safe, effective and engaging therapies to those in need of new treatment options."

"True innovation is built from a diversity of perspectives and experiences,” said David M. Solomon, Chief Executive Officer of Goldman Sachs. "Our Builders + Innovators Summit brings together a collective of impressive future leaders who are striving to drive meaningful change. For 150 years, Goldman Sachs has supported entrepreneurs as they launch and grow their businesses. That’s why we are pleased to recognize Mr. Klein as one of the most intriguing entrepreneurs of 2019."

In addition to honoring 100 entrepreneurs, the summit consists of general sessions and clinics led by seasoned entrepreneurs, academics and business leaders as well as resident scholars.

Click Therapeutics, Inc. develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. We are expanding the possibilities of medicine with Digital Therapeutics™ that combine clinical science with the power of software to create a new way to treat disease.  

Operating at the intersection of biology and technology, we use a proprietary platform-based approach to therapeutic development that leverages patient-centric design principles and innovative AI-based technologies to deliver a unique combination of engagement and clinical outcomes, consistently. Digital therapeutics on Click’s platform are regulated, clinically validated prescription mobile applications that can address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. 

Click Therapeutics, in collaboration with Otsuka, developed the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms, Rejoyn™. In October 2024, in response to FDA guidance on prescription drug use-related software (PDURS), we launched Click SE™ to extend our digital therapeutics platform and expertise to the development of software-enhanced drug™ therapies that combine software with pharmacotherapy to offer added clinically meaningful benefit to patients.

Our commitment to advancing digital medicine means we continually improve our platform technologies, ensuring we stay at the forefront of cognitive, behavioral, and neuromodulatory therapeutic innovation, to achieve the best possible outcomes for patients. Our diverse team of innovators—spanning clinicians, researchers, technologists, designers and more—works together to create cutting-edge digital therapeutics, united in the mission to transform patient care. For more information, visit www.clicktherapeutics.com and connect with us on LinkedIn.